Alerts will be sent to your verified email
Verify EmailEMCURE
Emcure Pharma
|
Pfizer
|
Eris Lifesciences
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
102.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
4.66 % | n/a | 0.0 |
Financials
|
|||
5 yr Average ROE
|
18.62 % | 18.39 % | 19.85 % |
5yr average Equity Multiplier
|
2.84 | 1.28 | 1.5 |
5yr Average Asset Turnover Ratio
|
0.91 | 0.6 | 0.58 |
5yr Avg Net Profit Margin
|
7.16 % | 24.04 % | 25.85 % |
Price to Book
|
4.71 | 5.17 | 7.16 |
P/E
|
38.92 | 31.52 | 60.23 |
5yr Avg Cash Conversion Cycle
|
-21.19 Days | -2.02 Days | -99.43 Days |
Inventory Days
|
82.48 Days | 49.44 Days | 26.22 Days |
Days Receivable
|
94.32 Days | 26.74 Days | 61.69 Days |
Days Payable
|
169.53 Days | 81.1 Days | 164.23 Days |
5yr Average Interest Coverage Ratio
|
4.17 | 170.95 | 94.87 |
5yr Avg ROCE
|
26.51 % | 23.56 % | 21.14 % |
5yr Avg Operating Profit Margin
|
19.04 % | 30.56 % | 34.25 % |
5 yr average Debt to Equity
|
0.95 | 0.0 | 0.29 |
5yr CAGR Net Profit
|
42.9 % | 65.36 % | 5.74 % |
5yr Average Return on Assets
|
6.6 % | 14.39 % | 15.49 % |
Shareholdings
|
|||
Promoter Holding
|
77.92 % | 63.92 % | 54.85 % |
Share Pledged by Promoters
|
0.04 % | 0.0 | 18.51 % |
Change in Promoter Holding (3 Yrs)
|
-0.16 % | 0.0 | 2.19 % |
Change in Mutual Fund Holding (3 Yrs)
|
-0.57 % | 3.65 % | 6.48 % |
Emcure Pharma
|
Pfizer
|
Eris Lifesciences
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
Acute vs Chronic
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|